GlassScriptPhysician profile
Cesar Carrizales
NPI 1639665839
$2,472.45
in general payments reported to CMS, 2019-2025
25 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.80 · 2022: $58.83 · 2023: $1,225 · 2024: $886 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $623.68 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $536.13 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $240.39 | 2023-2024 | |
| Pfizer INC. | $214.72 | 2023-2024 | |
| Lilly USA, LLC | $144.14 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Philips North America LLC | $69.77 | 2024 | (Az7) Lasers |
| Merck Sharp & Dohme LLC | $69.63 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Mylan Specialty L.P. | $62.67 | 2023-2024 | Yupelri |
| Glaxosmithkline, LLC. | $60.31 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $57.98 | 2024 | Inspire |
| Otsuka America Pharmaceutical, INC. | $57.43 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $43.88 | 2023 | Auvelity |
| Dexcom, INC. | $39.72 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.16 | 2023 | Tradjenta, Jardiance |
| Insulet Corporation | $31.21 | 2023 | Omnipod |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $29.67 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $27.48 | 2024 | Opsumit, Uptravi |
| Hologic Sales and Service, LLC | $18.05 | 2024 | Aptima, Thinprep 2000 Processor |
| Exact Sciences Corporation | $17.39 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $16.95 | 2024 | Injectafer |
| Corium, LLC | $16.92 | 2023 | Azstarys |
| Amgen INC. | $16.18 | 2023 | Otezla, Repatha |
| Organon LLC | $14.81 | 2024 | |
| Astellas Pharma US INC | $14.10 | 2024 | Veozah |
| Ironshore Pharmaceuticals INC. | $13.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Carrizales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.